1-(2,6-cis)-Trimethylpiperidin | 669-81-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(2,6-cis)-Trimethylpiperidin
• 英文别名: N-(2,6-trans)-Trimethylpiperidin；1-cis-2,6-Trimethylpiperidin；1c,2r,6-Trimethylpiperidin；(2S,6S)-1,2,6-trimethylpiperidine
• CAS: 669-81-8；2439-13-6；14231-79-9；16508-43-3
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: COSHJOZVKGAYBP-YUMQZZPRSA-N

物化性质

• 沸点：
  50-55 °C
• 密度：
  0.8319 g/cm3(Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

文献信息

• Anti-Viral Compounds
  申请人：DeGoey David A.

  公开号：US20100317568A1

  公开（公告）日：2010-12-16

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  描述了一种有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法、包含这种化合物的组合物，以及使用这种化合物治疗HCV感染的方法。
• DEUTERATED BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20170240585A1

  公开（公告）日：2017-08-24

  The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

  本发明提供了化合物的化学式(I)或化学式(II)：包括这些化合物的药物组合物以及使用这些化合物来治疗或预防由FXR和/或TGR5介导的疾病或紊乱的方法。
• ANTI-VIRAL COMPOUNDS
  申请人：AbbVie, Inc.

  公开号：US20140315792A1

  公开（公告）日：2014-10-23

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  描述了一种有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的过程、包含这种化合物的组合物以及使用这种化合物治疗HCV感染的方法。
• Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10696713B2

  公开（公告）日：2020-06-30

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

  本发明提供了式 I 的化合物、 包含这些化合物的药物组合物，以及使用这些化合物预防或治疗 FXR 介导或 TGR5 介导的疾病或病症的方法。
• BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20160145296A1

  公开（公告）日：2016-05-26

  The present invention relates to compounds of Formula (IA) and Formula (IB), and pharmaceutically acceptable salts thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.

表征谱图